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Delivering effective and non-toxic doses of bioactive materials that can aid in activating 
tissue regeneration to wounded tissue has proven to be an enormous challenge. This study was 
designed to produce a potential therapeutic recombinant protein by fusing two collagen binding 
domains to basic fibroblast growth factors (bFGF) through a collagenase cleavage site linker, so it 
can release the bFGF in a wound site by the action of this enzyme. The novel fusion protein was 
expressed in Escherichia coli BL-21 (E. coli) using traditional flask shaker and fed-batch 
cultivation. Cell lysate was purified by FPLC using Immobilized metal affinity chromatography 
and heparin heparin-affinity chromatography. Results showed that the desired fusion protein was 
expressed, but different truncated products were also evident including a protease within E.coil 

















I would like to thank God for his merciful and his continuous help over all the entirety of my life. 
Foremost, I would like to express my gratitude and thanks to my supervisor Dr. Bob Beitle for his 
guidance, continuous support and unlimited encouragement. I would also like to express my 
sincerest gratitude to my laboratory post-doctoral fellow, Dr. Ahmed Elmasheiti for his great 
assistance and support. Without him, it would have been far more tedious to acquire this degree. 
 
I must express my special gratitude to all the faculty, staff and students in the Ralph E. Martin 
Department of Chemical Engineering. Special thanks to Dr. Audi Thompson for the support and 
help while writing this thesis. Gratitude is expressed to my colleagues in Dr. Bob Beitle’s lab for 
their help and assistance in performing this work. I would also like express my gratitude to Dr. 
Josh Sakon from the Chemistry / Biochemistry department for supporting a part of my graduate 
assistantship to complete this degree. 
 
Finally, I dedicate my thesis to my wife Sura who has made countless sacrifices and has given 
unwavering support to actualize this goal. She has supported our family all the while pursuing a 
Ph.D. degree of her own and has been of immense help through thick and thin. I dedicate this work 
to the loving memory of my dad and my three late brothers. I also dedicate this work to my mother, 








TABLE OF CONTENTS 
1. Overview .................................................................................................................................... 1 
2. Literature Review ..................................................................................................................... 2 
2. 1. Proteins ................................................................................................................................ 2 
2.2 Overview of protein structure ............................................................................................... 3 
2. 3. Recombinant protein production ......................................................................................... 5 
2.4. Host selection ....................................................................................................................... 6 
2.4.1 E. coli host strains ........................................................................................................... 7 
2.5 Plasmid .................................................................................................................................. 9 
2.5.1 Composition of the plasmids ........................................................................................ 10 
2.5.2 The multiple cloning sites (MCSs) ............................................................................... 10 
2.5.3 The selectable markers ................................................................................................. 10 
2.5.4 The origin of replication site (ORI): ............................................................................. 11 
2.5.5 The promotor ................................................................................................................ 11 
2.6 Cultivation strategies ........................................................................................................... 12 
2.6.1 Batch fermentation ....................................................................................................... 13 
2.6.2 Fed-batch fermentation ................................................................................................. 15 
2.7 Purification .......................................................................................................................... 15 
2.7.1 General principles of affinity chromatography ............................................................ 16 
2.8 Wound Healing ................................................................................................................... 19 
3.  Scope of the project ................................................................................................................ 23 
4.  Materials and Methods .......................................................................................................... 24 
4.1 Strain and plasmid construction .......................................................................................... 24 




4.3 Plasmid recovery and validation ......................................................................................... 26 
4.4 Media and expression of targeted protein ........................................................................... 26 
4.4.1 Traditional shake flask .................................................................................................. 27 
4.4.2 Fed-batch cultivation .................................................................................................... 27 
4.5 Cell lysate preparation ......................................................................................................... 28 
4.6 His6-protein purification ..................................................................................................... 29 
4.7 Target protein determination assay ..................................................................................... 30 
4.7.1 SDS-PAGE electrophoresis .......................................................................................... 30 
4.7.2 Detection of His6-tag using protein tag stain reagent set ............................................. 31 
4.7.3 Western blot .................................................................................................................. 31 
5. Result and discussion .............................................................................................................. 34 
5.1 Traditional shake Flask cultivation ..................................................................................... 34 
5.2 Fed-batch cultivation ........................................................................................................... 37 
5.3 Purification of BFGF-CBD-CBD protein by heparin affinity chromatography ................. 42 
6. Conclusions and Recommendation ....................................................................................... 44 
7. References ................................................................................................................................ 45 
8. Appendix .................................................................................................................................. 50 









LIST OF FIGURES 
Figure 2.1 Example of the formation of a peptide bond by a condensation reaction between an α-
amino group (NH2) of one amino acid with a α-carboxyl group (COOH) of another[10]. ........... 3 
 
Figure 2.2 Schematic overview of the topics covered in this review, highlighting the multiple 
parameters (listed on the right) that can greatly impact the success of soluble expression [15]. ... 6 
 
Figure 2.3 General plasmid component in pUC18 plasmid structure as an example [2]. ............ 10 
 
Figure 2.4 β-lactam ring is hydrolyzed by bacteria [45]. .............................................................. 11 
 
Figure 2.5 Schematic of fed-batch fermentation set-up. The flow of oxygen and acid/base into 
the reactor are regulated by tower controls based on signals from probes, Nutrition feed that is 
essentially pumped into reactor is controlled using Applikon BioXpert software [59]. .............. 14 
 
Figure 2.6 Affinity chromatography binding and elution using antibody as an affinity agent. The 
filled circles represent the test analyte, and the open squares represent another non-retained 
sample [68].................................................................................................................................... 19 
 
Figure 4.1 Plasmid map of pAEM-1. ............................................................................................ 25 
 
Figure 4.2 Fast protein liquid chromatography (FPLC) system. .................................................. 29 
 
Figure 4.3 Steps of western blot gel preparation and stock diagram [78] .................................... 32 
 
Figure 5.1 FPLC chromatogram of cell lysate prepared by traditional shaker flask method using 
nickel loaded HiTrap IMAC FF column. ...................................................................................... 34 
 
Figure 5.2 SDS-PAGE gel shows IMAC fractions results of cell lysate prepared by the 
traditional shaker method. A. Gels stained with Pierce™ 6xHis Protein Tag Stain Reagent. B. 
Gels stained with Coomassie Brilliant Blue staining solution. Results for both methods included 
lane 1– molecular weight marker; 2– cell lysate after expression; 3– junk protein fraction; 4– 12, 
fraction 20-28 respectively. .......................................................................................................... 35 
 
Figure 5.3 bFGF-CBD-CBD fusion protein carton shows the molecular weight of bFGF and 2 




Figure 5.4 Western blot of interesting IMAC fractions resulting in lysate prepared by traditional 
shaker methods.  1 – molecular weight marker; 2 – positive control (Hisx6-tag -protein; 3–cell 
lysate after expression; 4– junk protein fraction; 5 – 11, fraction 23 to 29 respectively. ............. 36 
 
Figure 5.5 Coomassie Brilliant Blue staining and Western blot of the interesting heparin fractions 
of lysate prepared by traditional shaker methods. For both methods; 1 – molecular weight 
marker; 2– positive control (Hisx6-tag -protein); 3- cell lysate; 4–10 fraction 1 to 7 respectively 
of 62.5 mM imidazole fraction. .................................................................................................... 37 
 
Figure 5.6 Biomass production of E coli BL-21 by using; A- Fed-batch fermentation method; B- 
Traditional shaker method. ........................................................................................................... 38 
 
 Figure 5.7 FPLC purification chromatogram of cell lysate prepared by fed-batch fermentation 
using nickle-loaded HiTrap IMAC FF columns. .......................................................................... 40 
 
Figure 5.8 SDS-PAGE gel shows IMAC fractions of cell lysate prepared by the fed-batch 
method. A. Gel stained with Pierce™ 6xHis Protein Tag Stain Reagent. B. Gel stained with 
Coomassie Brilliant Blue staining solution. For both methods, lane 1 – molecular weight marker; 
2 –cell lysate after expression; 3 –11, fraction 9 -16 respectively. ............................................... 41 
 
Figure 5.9 Coomassie Brilliant Blue staining and Western blot of a riveting IMAC fraction of the 
lysate prepared by the fed-batch method. For both methods. 1 – molecular weight marker; 2–9 
fraction 9 to 16 respectively; 10– positive control (Hisx6-tag -protein). ..................................... 41 
 
Figure 5.10 FPLC purification chromatogram of cell lysate prepared by the fed-batch method 
using HiTrap Heparin HP column. ............................................................................................... 42 
 
Figure 5.11 Coomassie Brilliant Blue staining and Western blot of the interesting heparin 
fractions of lysate prepared by methods. For both methods; 1 – molecular weight marker; 2– 










LIST OF TABLES 
Table 1.1 Common ligands used in affinity chromatography [68]. .............................................. 17 
 
Table 2.2 Normal wound healing phases and major types of cells involved in each phase, and 





This study is designed to express a novel therapeutic recombinant protein by fusing two collagen 
binding domains to basic fibroblast growth factors bFGF with a collagenase cleavage site linker. 
Collagen-binding domain serves as a shuttle to deliver effective nontoxic doses of fibroblast 
growth factors bFGF to the wound site. Hisx6-tag has been placed at N-termnial to facilitate 
purification by immobilized metal affinity chromatography. Also, heparin-affinity 
chromatography purification has been performed in the investigation experiment to prove our 
















2. Literature Review 
2. 1. Proteins 
 Proteins are essential macromolecules in living systems and serve diverse functions in all 
biological processes ranging from DNA replication [1], metabolic processes in the cell, transport 
and storage, mechanical support and immune protection, and movement, transmitting nerve 
impulses, growth control and differentiation, as well as the converting one molecule into another 
[2, 3]. 
The word "protein," is derived from the Greek adjective proteios, meaning the class of 
organic compounds that is present in all living cells in different forms such as skin, hair, callus, 
cartilage, muscles, tendons and ligaments [4, 5]. The word protein was mentioned for the first 
time in 1838 in a letter sent by chemist Jöns Jakob Berzelius to Dutch chemist Gerhardus 
Johannes Mulder. Berzelius carried out an elemental analysis of common proteins and found that 
nearly all proteins had the same empirical formula. Mulder worked on identifying the products of 
protein degradation such as the amino acid leucine which has a molecular weight of 131 Daltons. 
During that time, Antoine Fourcroy and other researchers recognized proteins as a different class 
of biological molecules that were distinguished by their ability to coagulate or flocculate when 
treated with acid or heat [6]. Proteins were discovered to be large macromolecules, they consist 
of between 50 to 10,000 residues. Some proteins even exceed one million residues [5, 6]. Since 
the average molecular weight of a single residue is 120 Dalton,  the approximate protein 
molecular weight is anywhere between  10 thousand to a few million Daltons [5, 7]. Proteins are 
linear polymers consisting of monomer units of amino acids which are connected by a type of 




[2, 7, 8]. A peptide bond is a bond formed by the reaction of an α-amino group (NH2) of one 
amino acid with the carboxyl group (COOH) of another, as shown below in Figure 1 [9]. 
 
Figure 2.1 Example of the formation of a peptide bond by a condensation reaction between an α-
amino group (NH2) of one amino acid with a α-carboxyl group (COOH) of another[10]. 
A polypeptide is a single linear polymer chain of amino acids bonded together by peptide 
bonds between the carboxyl and amino groups of adjacent amino acid residues [9]. Proteins 
consist of one or sometime multiple polypeptides which can naturally fold after being 
synthesized into a specific three dimensional to form either globular or fibrous protein to do a 
biological function [11, 12]. 
2.2 Overview of protein structure 
 All proteins are categorized at four levels of structure (primary, secondary, tertiary, and 
quaternary) [13]. There are 20 amino acids that exist naturally in living organisms. In some 
cases, these amino acids are chemically modified after protein synthesis [1, 2]. It is possible to 
build a large number of different proteins from 20 amino acids. For example, 10 different 




[5]. The primary structure represents the linear sequence of amino acids residues.  Every protein 
has a unique sequence of amino acids that is held together by peptide bonds. The primary 
structure is defined as a nucleotide sequence of a gene, which is encoded in the genetic code of 
messenger RNA for that protein [5, 13]. The secondary structure is formed by the primary 
structure which refers to the linear configuration of the amino acids. In this structure, the 
repeating amino acid sequence is stabilized by hydrogen bonds between residues that are not 
widely separated. There are two types of secondary structure; an alpha helix, and a beta sheet 
[14]. An alpha helix is a coiled structure stabilized by hydrogen bonds which form through 
interactions between the NH group of one residue and CO group of a neighboring residue. 
Basically, the carboxyl group of one residue bind to the amino group of another residue located 
four residues down in the amino acid sequence through hydrogen bond. In contrast, hydrogen 
bonds can form between parallel chains of polypeptides forming a beta sheet structure. Parallel 
beta-sheet structures are more stable than an alpha-helix. Hydrogen bonds between parallel 
amino acid chains stabilize the beta sheets allowing flexibility and resistance to damaging its 
integrity by being stretched [2, 11, 12].  
Proteins also can fold extensively into a more stable complex three-dimensional 
configurations called a tertiary structure. This kind of 3D structure is maintained by covalent 
bonds, hydrogen bonds, disulfide bonds, ionic bonds, and hydrophobic interactions between R 
groups that define each amino acid. The R groups organize in a way that the hydrophobic side 
chains are in the interior and the hydrophilic groups are exterior to help form three-dimensional 
configuration of a protein [1, 5]. When multiple polypeptide chains join together, they form a 
quaternary structure. This structure is known as a protein complex and is formed by disulfide 




that hold the structure in place.  Hemoglobin is an example of a macromolecule with quaternary 
structures which consists of four subunits [7].  
2. 3. Recombinant protein production 
Previously, a large amount of plant and animal tissues or large volumes of biological 
fluids were normally used to purify small amounts of a given protein from a natural source. 
Those time consuming and complicated methods have been eliminated by expressing 
recombinant proteins in microbial systems [15]. Recently, when researchers needed a protein to 
use in their project, they immediately think of how to obtain it in a recombinant form rather than 
extracted from natural sources. The ability to express and purify the desired recombinant protein 
in large quantities allows for its biochemical characterization and to be used for further 
application at both a laboratory or industry level [16]. Theoretically, obtaining a recombinant 
protein is a straightforward process. It can be done by cloning a gene of interest in the desired 
expression vector, and transforming it into the selected host and inducing it to produce the 
protein. Following this procedure, the protein is ready for purification and characterization 
(Figure 2.2). On the other hand, several issues may arise such as slow growth, inclusion body 
formation, producing inactive protein or not even producing the protein of interest at all [15, 17]. 
This research focused on the production and purification of a new basic fibroblast growth 
factor fused to two collagen binding domains expressed in E. coli BL21. It is hoped that a 






Figure 2.2 Schematic overview of the topics covered in this review, highlighting the multiple 
parameters (listed on the right) that can greatly impact the success of soluble expression [15].  
2.4. Host selection  
The choice of host is an important step to produce a recombinant protein. Typically, a 
distinctive vector for protein expression, selection marker, and origin of replication are basic 
properties to be considered.  A successful production process of heterologous proteins depend on 
the proper host [18].  On the other hand, the molecular properties of each particular protein such 
as protein size and 3D structure affect the selection of the host system. For example, proteins 
which have multiple disulfide bonds such as insulin are cloned into an easily fermentable 




eukaryotic systems [19].  Therefore, the suitable expression system for each individual of 
recombinant protein products need to be optimized individually. 
In general, two major strategies can be used for the expression of heterologous genes: 
episomal vectors and chromosomal integration.  There are advantages and disadvantages to each 
method.  High copy number vectors can be used for plasmid (episomal) systems, but antibiotics 
are typically required as an addition to the media. In their absence, the plasmid may be lost. In 
contrast, chromosomal integration results in a lower copy number, but the gene copies are 
maintained in the absence of the selection marker [18]. Previous studies show that both secreted 
and intracellular proteins have been successfully expressed at a large scale [20]. There are 
several genetically engineered eukaryotic and prokaryotic cells which are capable of expressing a 
wide range of recombinant proteins. The most common host for intracellular recombinant protein 
expression is Escherichia coli, while mammalian cells are used for extracellular recombinant 
protein expression. Yeast especially Saccharomyces cerevisiae can produce both intracellular 
and extracellular products [19]. Pharmaceutical industries tend to prefer extracellular protein 
production over intracellular proteins due to the difficulties of downstream processing to extract 
the target proteins through lysis and chromatography [20]. Prokaryotic systems like Escherichia 
coli (E. coli ), which has been used in this study, genetically engineered yeast cells, genetically 
engineered fungi, as well as insect and mammalian cells are the main recombinant protein 
expression systems used in bio-pharmaceuticals industries [19]. 
2.4.1 E. coli host strains 
Although there are several host systems available for recombinant protein expression, the 
preferred choice is E coli as an initial host [21]. It is the most widely used of all prokaryotic 




It is easy to handle and culture at high density on inexpensive substrates with a very short 
doubling life cycle time [19, 22, 23]. E. coli is an affordable host that has been used often to 
minimize the cost of therapeutic protein production [24, 25]. It has remarkable ability to produce 
a large amount of recombinant protein [26]. The first recombinant DNA (rDNA) bio-
pharmaceutical, that enabling the approval of Eli Lilly’s rDNA human insulin was produce in E. 
coli at 1982 [27].  
The most important factor for recombinant expression is the genetic background of the 
host. Absence of the most harmful natural proteases in expression strains is very important to 
maintain the stability of the plasmid expression level. E. coli BL21[28, 29] is an advantageous 
and common strain which has been proven outstanding in standard recombinant expression.  It is 
an efficient E. coli B strain which can grow in minimal media with high density. The beauty of 
this strain is non-pathogenicity which is unlikely survive and cause disease to the host tissue 
[30]. BL21 lacks two proteases (ompT and lon) that may attack recombinant proteins after 
expression [31, 32]. There are other derivatives of BL21 such as recA negative strains(Novagen 
BLR strain) is used for the stabilization of target plasmids holding repetitive sequences, trxB/gor 
negative mutants (Novagen Origami and AD494 strains) used mainly for inducing cytoplasmic 
disulfide bond formation, lacY mutants (Novagen Tuner series) regulating the adjustable levels 
of protein expression and mutants (Avidis C41(DE3) and C43(DE3) strains) used for the soluble 
expression of inclusion body and membrane proteins production [28]. 
Overexpression of heterologous protein in E coli often result in an aggregation form of an 
expressed protein called inclusion bodies. Inclusion bodies are known as a large proportion of 
the target protein accumulating in dense insoluble aggregates. This generally occurs because of 




cytoplasm such as high local concentration of polypeptide chains emerging from ribosomes and 
inefficient folding and unavailability of chaperones [33]. Minimizing inclusion body formation is 
preferred to maximize the yield of well-folded active protein in soluble form. Collecting the 
insoluble fraction, in some cases, can be used to rebuild and produce large quantities of 
biologically active protein. There are several clinically important hormones, and peptides that 
have been produced using this approach since the late 1970s [34]. Most pharmaceutical 
industries produce recombinant proteins as inclusion bodies using E. coli systems. Complete 
denaturation of inclusion bodies, chemical refolding, and purification are required for the 
isolation of the active protein form [35, 36]. Despite the difficulty of recovering heterologous 
proteins from inclusion bodies, there are several advantages of this phenomenon such as 
decreased proteolytic activity and higher yield [19]. Although the methods associated with 
insoluble protein production have commercial significance, it is still less well developed than the 
corresponding methods for the production of the soluble one.  
2.5 Plasmid 
Plasmids are a biological delivery vector of a small extrachromosomal DNA that can 
transfer between prokaryotic and/or eukaryotic host cells. On the other hand, plasmids are a tool 
for inserting a foreign gene(s) into the host cells. Inside, the plasmid is able to replicate 
independently of host cell replication, however, it utilizes the cell`s contents such as enzymes 
and ribosomes for its transcription (mRNA) and translation (amino acids) respectively. Most 
plasmids are circular in shape and vary in sizes from 1,000 to 20,000 DNA base pairs. Plasmids 
are easy to be opened by restriction enzymes without falling apart. This characterteristic makes it 




genetically modified plasmids which are used for the production of recombinant products such as 
enzymes, vaccines, and supplements that are applied in different biological fields [37, 38]. 
2.5.1 Composition of the plasmids 
There are very important DNA regions that must be present in the plasmids to be 
maintained inside the host cells, replicating spontaneously, and expressing the target gene [39] 
(figurer 2.3).  
 
Figure 2.3 General plasmid component in pUC18 plasmid structure as an example [2]. 
2.5.2 The multiple cloning sites (MCSs) 
Multiple cloning sites are also known as polylinkers which contains many unique specific 
sequences for different restriction enzyme to open the plasmid to insert and clone the desired 
gene to produce the protein of interest [40, 41](Figure 3.2).  
2.5.3 The selectable markers 
 Even when applying modern molecular biology techniques, only very few cells can accept the 
plasmids (around one per ten thousand cells). To ensure the plasmids are successfully 




the plasmids. The most commonly used markers are antibiotic resistance markers [42, 43]. In 
case of ampicillin markers, the plasmid carries a beta-lactamase gene which breaks down the 
beta-lactam bond; subsequently, deactivating the action of ampicillin when the cells grow in  
ampicillin-containing media [44] (Figure 2.4).  
 
Figure 2.4 β-lactam ring is hydrolyzed by bacteria [45]. 
2.5.4 The origin of replication site (ORI): 
The plasmid initiates self-replication at this site to increases in number inside the host cell 
[46]. The number of plasmids is determined by the origin replication type. The type of ORI 
determines the number of copies. Origin of replication of plasmid pUC19 produces 500 to 700 
copies per each bacterial cell whereas, ORI of plasmid  pBR322 produce only 15-20 copies [43].    
2.5.5 The promotor 
It is a stretch of DNA sequenceing that encodes to RNA polymerase sitting directly 
before the MCSs. In this place, the plasmid starts its own expression since it contains a binding 
site for RNA polymerase. Without induction, the promotor cannot spontaneously start the 




IPTG or arabinose are added to the media at a determined time which will cause deformation to 
the blocked region, resulting in opening and binding to the RNA polymerase. In case of the 
presence of Lac operon, induction is difficult if glucose is used as a metabolizable carbon source 
in rich media. Lactose enhance induction of the system for protein expression. Therefore, if 
lactose and glucose are present in the media, full induction of the system occurs until the 
remaining glucose is consumed [47]. There are eight major promoters used for recombinant 
protein expression [48]; 
1- IPTG-inducible promoters (Lac, LacUV5). 
2- The auto inducible trp promoter. 
3- The hybrid promoters tac and trc. 
4- The heat-inducible phage λ promoters PL and PR. 
5- The tetracycline-inducible promoter. 
6- The arabinose-inducible PBAD promoter. 
7- The cold-inducible cspA promoter. 
8- T7 promoter. 
2.6 Cultivation strategies 
Two culturing strategies have been used reqularly for the production of recombinant 
protein; batch and fed-batch cultivations. In the case of batch culture, higher growth rates will 
decrease the media efficacy to maintain the same level of growth for longer periods, and acetate 
will accumulate at a higher rate. High cell density initiates several issues such as a substrate or 
product inhibition, nutrient inhibition, and dissolved oxygen starvation in aerobic conditions [49, 
50]. Using fed-batch can minimize certain problems associated with high-density growth and can 




aims to scale up protein production in a minimal frame time, fed-batch fermentation should be 
done in bioreactors that possess useful hardware such as pH probes to control the production of 
biomass instead of using manual control (Figure 2.5).  For example, using a probe to control a 
pH of 6.0 will lead to a higher biomass growth production [52].  Also, adding other probes that 
relate growth to feeding may lead to efficient substrate use [53]. In general, the term "batch" is 
often used to refer to both batch and fed-batch fermentation [54]. 
2.6.1 Batch fermentation 
Batch fermentation is an easy to operate, inexpensive, and poses a very low chance of 
contamination. Broadening the use of this technique by the researcher should result in 
recombinant proteins from bacterial, mammalian, and insect cells with high yields [55]. All 
necessary medium components and inoculum should be added at the same time at the beginning 
of the process and not during the fermentation process [56]. This technique can be accomplished 
by the use of a bioreactor. The difference between using traditional, simple flask method and a 
bioreactor in a batch cultivation is the ability to monitor and control. Basically, in flask methods 
all culture components include media, bacteria, substrates (that are added at the same time in one 
batch for a certain period without any biomass), pH, temperature, and dissolved oxygen monitor 
and control [57]. In contrast, biomass, pH, temperature, and dissolved oxygen can be monitored 
and controled using the bioreactor method. A host with engineered a plasmid that contains the 
DNA of interest are used to inoculate a suitable media in a special, sterile glass tank of 
bioreactor. This tank is closed tightly with a steelhead. This head contains a stirrer extending 
down close to the bottom of the glass tank to combine the culture component contrary to the 




oxygen supply, pH electrode, dissolved oxygen and temperature probes (Figure 2.5). 
 
Figure 2.5 Schematic of fed-batch fermentation set-up. The flow of oxygen and acid/base into 
the reactor are regulated by tower controls based on signals from probes, Nutrition feed that is 
essentially pumped into reactor is controlled using Applikon BioXpert software [59]. 
 
All these components connect to a computer loaded with software that monitor and 
control, regulating agitator speed and oxygen flow rate, as well as maintaining the optimum heat 
and pH level by addition of an acid or base. The advantage of using the bioreactor method is the 
cultivation period after plasmid induction to express the target protein. This method allows the 
growth to continue for several days compared to flask shaker which is harvested after five to 
seven hours from plasmid induction. Plasmid induction for gene expression is carried when 
optical density (O.D) at 600 nm reaches about 0.6 which represent the early time of the 




 2.6.2 Fed-batch fermentation   
This technique has been used to achieve high cell density to produce a high yield of 
recombinant protein. High cell density fermentation is the main target of bioprocess engineering 
to increase the yield of recombinant proteins production. It is the main consideration to increase 
the protein expression in E. coli [58]. The main differences between batch and fed-batch 
processes are materials such as media or carbon sources can be added during the batch run. 
Certain issues can arise from increasing cell concentration during cultivation such as a substrate 
or product inhibition, nutrient inhibition, or dissolved oxygen limitations [49]. Therefore, fed-
batch operation is applied to minimize high cell density related issues. Also, the fed-batch can 
continue for a few days longer which increases the overall yield of recombinant protein and 
dropping the production cost [51]. Fed-batch process like batch process, biomass, pH, 
temperature, and dissolve oxygen can be monitored and controlled by a special bioreactor 
software like Applikon BioXpert software. 
2.7 Purification 
There are an extensive amount of complicated details and specialized equipment 
designed for protein isolation and purification. These pieces of equipment become more 
convenient and automated. They are controlled by microprocessors and easy to operate [60]. 
Facilitating the production of high purity and well characterization of recombinant proteins is a 
major task for the pharmaceutical industry [61]. 
Fast protein liquid chromatography (FPLC) has been widely used for purified 
recombinant proteins. In short, cell lysate was loaded to the column filled with a cross-linked 
resin that had ligands on its surface (depending on the target protein). The target protein then 




to wash away or caused a decrease in movement through the column. In the end, elution of the 
target protein by washing the column with elution buffer which contains a type of material 
triggering an interference of the binding of the target protein to the column resin. Purified protein 
was then collected in small fractions for further analysis  [59].  
 Affinity chromatography is a type of liquid chromatographic technique. To facilitate the 
purification of recombinant protein, affinity tags have been genetically attached to targeted 
protein. Typically, the DNA encoding for the additional tag or affinity tail is fused to a gene of 
interest within the genes encoding for the target protein to express with the tag during 
fermentation producing the protein of interest with affinity tag complex. Attaching a peptide 
affinity tags to a recombinant protein has been widely used to facilitate protein purification using 
several methods such as affinity, ion exchange, hydrophobic, covalent, and metal-chelating 
separations [62]. This strategy can provide a high level of purification with a hundred- or even 
thousand-fold more of using traditional affinity methods [63]. Polyhistidine tag (His6-tag) is an 
example of an affinity tag which has been broadly used to facilitate recombinant protein 
purification. It is also known as Immobilized Metal Affinity Chromatography (IMAC). Histidine 
has a strong affinity to immobilized metal ions such as cobalt, copper, and zinc with +2 ionic 
charge. The basic principle of this interaction is that histidine has an imidazole ring that can form 
strong pi interaction bonds with the metal ions [64]. His6-tag is also used as an expression 
marker by using a commercially available His6 antibody. Purification using this method can 
produce 90-99% pure targeted protein from the original cell lysate [61, 65, 66].  
  2.7.1 General principles of affinity chromatography  
Affinity chromatography is a type of liquid chromatographic technique which is a 




made mostly from a biological related agent. In this method, specific reversible interactions that 
occur in many biological systems such as the binding of an enzyme with a substrate or an 
antibody with an antigen is used in the retention of a solute [67]. There are a surplus of natural 
and synthetic molecules of non-biological origin which have also been used in affinity 
separations. Regardless of their origin, all these ligands can be placed into one of two categories: 
high-specificity ligands or general ligands. Ligands that are commonly used in affinity 
chromatography are listed in Table 2.1.  
Table 1.1 Common ligands used in affinity chromatography [68].  
 
The base of these interactions is accomplished by placing one of a pair of interacting 
molecules onto or within a solid support as an immobilized agent which is used in the stationary 
phase. This support should have low non-specific binding for sample components, it should be 
easy to modify for ligand attachment, and it should be stable under the flow rate, pressure, and 
solvent conditions that will be employed in the analysis or purification of samples. Depending on 
which affinity chromatography performance is used a low- or a high technique, there are several 
types of support materials such as a carbohydrate-based gel or one of several synthetic organic-




affinity column the ability to interact or bind to compounds in a sample [68]. There are two 
methods for solutes elution isocratic and gradient. A step gradient for elution is the most 
common methods used in performing affinity chromatography by injecting a sample onto the 
affinity column in the presence of a mobile phase that has the right pH and solvent composition 
for specific solute–ligand binding [21]. This solvent, which represents the weak mobile phase, is 
called the application buffer of the affinity column. While the sample is carried through the 
column by the application buffer, target compounds bind to the affinity ligand due to the high 
selectivity of the solute–ligand interaction. The other components of the sample tend to pass 
through the column without being retained. After the non-retained components are washed 
completely from the column, the elution step is performed to retain the target a solute using a 
solvent that displaces them from the column by dissociating a solute–ligand complex interaction 
(Figure 2.6). This solvent which represents the strong mobile phase for the column is called an 
elution buffer. After the interesting solutes elute from the column, measurement are preformed 





Figure 2.6 Affinity chromatography binding and elution using antibody as an affinity agent. The 
filled circles represent the test analyte, and the open squares represent another non-retained 
sample [68]. 
2.8 Wound Healing 
Wound healing is a normal biological process in the human body to repair an injured 
tissue or skin. It is achieved through four highly programmed phases in proper sequence and 
specific time: hemostasis, inflammation, proliferation, and remodeling.  A brief summary of 
cellular and bio-physiological events of wound healing process is shown in Table 2.2. These bio-




platelets, inflammatory cells, cytokines, growth factors, as well as matrix metalloproteinases and 
their inhibitors [69, 70]. For a typical wound healing outcome, all four phases must occur in the 
proper sequence.  
 Table 2.2 Normal wound healing phases, major types of cells involved in each phase, and 
specific events involved [70]. 
 
Wound healing can be a simple break in the epithelial integrity of the skin or deeper 
extending into subcutaneous tissue causing damage to other tissues such as tendons, muscles, 
vessels, nerves, parenchymal organs, and even bone. However, wound healing is classified into 
two major types: chronic and acute.  In the acute type, wounds are healed normally through 




On the other hand, chronic types proceed through portions of the repair process causing 
improper tissue repair results [71]. This type of wound healing process is affected by many 
factors such as oxygenation, infection, age and sex hormones, stress, diabetes, obesity, 
medication, alcoholism, smoking, and nutrition. Understanding the effect of these factors on 
repair may lead to developing new therapeutics that improve wound healing and resolve 
impaired wounds [72]. Typical therapeutic wound healing implants should have the ability to 
adhere and conform to the wound site, enable regrowth of epidermis, aid in the accumulation of 
fibroblasts, endothelial cells, and wound healing regulatory cells into the wound site to speed the 
healing process [73]. 
Wound healing largely remains a difficult pathology challenge in defeating related 
clinical issues. To reduce the wound burden, several synthetic and biological materials have been 
used to mediate tissue regeneration. Despite the advantages of using these materials to speed up 
the healing process, it can generate several issues like infection issues such as compatibility and 
infection considering the biological materials or the tissue from donors [74]. Looking for 
alternative bioactive material is essential because it has the ability to enhance the tissue 
regeneration process without the use of synthetic materials or the dependence of donors [75]. It 
has been found that some material such as growth factors can activate cellular regeneration. The 
main issue with this alternative is that it cannot be administered through usual drug delivery 
methods due to their limited target specificity and short half-lives in vivo [76]. Many therapeutic 
strategies have been used such as collagen in tissue engineering to aid in wound healing. It has 
been found that collagen can provide structural stability and increase cellular attachment [74]. To 
achieve a great deal of triumph and reduce both problems of specificity and short half-lives, 




this versatile therapeutic protein, the binding domain can be used as an “anchoring unit” for in 
vivo applications and maintaining growth factor activity and its concentration at the target site 
[77]. It has been shown that growth factors and cell binding peptides fused to biomaterial carriers 
can achieve biomolecular recognition of cells in addition to interacting with surrounding tissues 
[75]. Therefore, new therapeutic approaches have been designed in this project to produce basic 
fibroblast growth factors fused to two units of collagen-binding domain (bFGF-CBD-CBD) with 




















3.  Scope of the project 
Since there is significant interest in explaining the use of FGF fusion proteins, this project 
has been designed to express and purify a fusion of FGF with two collagen binding domain 
(CBD). This project has been designed in to express, produce, and purify an innovative 
therapeutic protein by fusing basic fibroblast growth factor to two units of collagen-binding 
domain (bFGF-CBD-CBD) with a protease cleavage site between FGF and CBD units to care for 
both acute and chronic wound. Two collagen binding domains (CBD) allows for efficient uptake 
growth factors and deliver it to the wound site. After FGF is delivered to wound site, it can be 















4.  Materials and Methods 
4.1 Strain and plasmid construction 
E. coli BL21 (DE3) strain was purchased from New England Biolabs Inc and used as a 
host to produce targeted recombinant protein. For expression plasmid construction, the 
pBAD/Myc-His plasmid was purchased from Invitrogen Life Technologies. The pBAD/Myc-His 
vector is a pBR322-derived expression vector. The araBAD promoter (P bad) provides tight, 
dose-dependent regulation of heterologous gene expression (Guzman et al., 1995) because the 
araC gene encodes the regulator protein for tight regulation of the P bad promoter (Lee et al., 
1981). Ampicillin resistance gene lactamase allows selection of the plasmid with an antibiotic. 
Restriction maps and multiple cloning sites (MGS) of the plasmids are presented in Appendix 8-
1 and the DNA sequence of PAEM-1 as well. 
 E. coli chemically competent Bl-21 cells from Invitrogen were used. Competent cells 
were transformed with recombinant pAEM-1 plasmid.  This plasmid, pAEM-1, contains the 
genetic information for the recombinant protein bFGF-CBD-CBD (424 amino acids), as depicted 
in Figure 4.1. Synthesized DNA sequence for bFGF-CBD-CBD protein was purchased from IDT 





Figure 4.1 Plasmid map of pAEM-1.   
4.2 Cloning of target gene 
 Heat shock method was used for transformation of pAEM-1 to E coli-BL21. Gene of 
interest and pBAD have the same restriction sites. The process starts by adding 20 μL of the 
plasmid in three different tubes containing NcoI + EcoRI (1-3 µl from each enzyme) and 2.5µl of 
10× of digestion buffer. The samples were incubated for 1 hour at 37°C and then subjected 
agarose gel electrophoresis to validate restriction. The digested plasmid and target gene were 
recovered from the gel to provide material for ligation. Samples were heated at 65°C for 10 
minutes to denature restriction enzymes. Then, 8 µl of recovered plasmid from gel, 2 µl of 
recover gen from gel, 1 µl ligase enzyme, 2.5 µl ligase buffer, and 1.5 µl of ddH2O were added 
was mixed in one tube and incubate at 16°C overnight. To validate the ligation process, agarose 




Transformation of a plasmid carrying the target gene to E. coli was done by heat shock 
method as mentioned earlier. E coli-BL21 strain tube containing 20 ul of bacteria was taken from 
-80 and incubate for 30 minutes in ice to thaw.  After that, 2 - 5 µl of plasmid was added to the E 
coli-BL21 strain and incubate in ice for another 30 minutes. The mixture was incubated exactly 
for 10 seconds at 42°C and then placed on ice for 5 minutes. Transformed bacteria was mixed 
with 1ml SOC outgrowth medium (New ENGLAND BioLabs, USA) without ampicillin and 
incubated in a shaker incubator for 1 hour. After the incubation time was over, 100 µl was spread 
on ampicillin containing LB agar media and incubated at 37°C for overnight. The presence of 
colonies on ampicillin containing LB agar proved that the plasmid successfully transformed of E. 
coli. A single colony was used to inoculate 5ml of ampicillin containing LB media and incubate 
at 37°C for overnight. 
4.3 Plasmid recovery and validation 
To prove that bacteria up took the same plasmid, the plasmid was recovered from 
bacteria, and gel electrophoresis showed the size of the engineered plasmid. Plasmid recovery 
was done by using Plasmid Mini Kit purchased from Qiagen. The protocol was provided by 
manufacturer. The process starts by inoculating 5 ml of LB media with 100µg/ml ampicillin and 
incubating at 37°C overnight. Cells were collected by centrifugation at 14000 rpm for three min. 
Plasmid extraction protocol was followed this step to collect recovered plasmid. A part of 
recovered plasmid was subject to run through agarose gel electrophoresis for validation. 
4.4 Media and expression of targeted protein 
 Luria-Bertani (LB) broth was used for all plates and seed cultivations. A single colony of 
E. coli BL21 with pBAD Sakon Collagenase Eco47III spanning plasmid was picked from a plate 




ampicillin as an initial growth seed culture. The culture was incubated at 37 °C and shaken at 
250 rpm overnight. The goal of using multiple types kind of cultivations was to monitor growth 
and protein expression using both open and closed systems. 
4.4.1 Traditional shake flask  
This experiment was performed by using 2.5 ml of shake flask overnight to culture the 
inoculated 500 ml of the media in every shake flask experiment. The growth was kept at a 
temperature of 37 °C. Media was supplemented with 75 μg/ml ampicillin. L-arabinose was used 
to induce the plasmid at the mid-exponential phase of growth to start expression when the optical 
density (OD) reached ̴ 0.6 units (at 600 nm) about 2 hours from inoculation. Cells were collected 
after 4 hours from induction to proceed in further steps. 
4.4.2 Fed-batch cultivation 
  This trial was set as a primary experiment for a future scale-up plan. 10 ml of shake flask 
culture was used to inoculate 100 ml of the media overnight. The following day, the 100 ml of 
shake flask culture which had grown at 37 °C used to inculcate 3 L of bioreactor tanks loaded 
with 1 L of LB media supplemented with 100 μg/ml ampicillin to maintain selection. Inducer (L-
Arabinose) was added when optical density (OD) reached ̴ 0.6 units (at 600 nm). One liter of LB 
media supplemented with 100 μg/ml ampicillin, 2mg/ml of magnesium chloride, 10 ml of 
sterilized glycerol solution and L-Arabinose was included for inducing more growth cells in all 
of the fed-batch experiments.  The fed media was also supplemented with 1 ml antifoam to 
control foaming and an additional few drops was deemed necessary when the foam reached a 
level about 2 inches from the top of the reactor.  
 Each experiment can be broken down into a batch and a feeding phase. In the batch 




phase began. Fed start point had been set depending on how efficient and how quickly the 
growing bacteria reached the lag phase using only the initial carbon substrate in the start media. 
An increase in pH and a sharp decline in dissolved oxygen level indicated that most carbon 
sources were consumed in the system.  In the fed-batch experiments, these events occurred at the 
same time and were monitored by the Applikon bioreactor software. These two events that had 
been observed happened between 7 to 8 hours after inoculation, so the feeding is started at a 
specific time frame to provide more nutrients. In this experiments E coli-BL21 was used as a 
host, and a shorter lag phase (2.5 hours) was observed. The feeding began around 7 hours from 
bioreactor inoculation. Using different hosts may change the time that bacteria take to reach the 
lag phase. For example, if the bacteria take 4 hours to reach a long lag phase, the feeding should 
begin at 8 hours from inoculation.  
The feeding profile that is proposed by Korz et al. (1995) and Lee et al. (1997) was used 
in this experiment and was programmed into the Applikon software. Cells were collected after 
20 hours from induction to proceed with further steps. 
4.5 Cell lysate preparation 
After fermentation, cells were collected by centered at 4 °C, 4,500 rpm for 45 minutes. 1 ml of 
bacteria pellet resuspension was added in 5 ml of 10 mM of phosphate buffer with 0.5µl of a 
cocktail protease inhibitor. Buffer to pellet ratio was kept constant and was then determined by 
pellet volume. Sonicator was used to prepare cell lysate. This process was performed by lysate of 
the cell in an ice bath. The lysate cell was and spun again by a centrifuge machine with the same 
speed and condition. The solid fraction was discarded, and the lysates were kept at -20 °C. Then, 
the sample was centrifuged for 5 minutes. The supernatant was collected and filtered once more 




4.6 His6-protein purification 
Lysates were purified using the Fast protein liquid chromatography (FPLC) system from 
ӒKTA Amersham Pharmacia Biotech (Figure 4.2).  
 
Figure 4.2 Fast protein liquid chromatography (FPLC) system (Image by author). 
Cell lysates were filtered through a 0.20 μm filter. HiTrap IMAC FF columns from GE 
Healthcare-Bio-Sciences (Uppsala, Sweden) were loaded with nickel. This column is received 
with 20% ethanol as a preservative. Ethanol was washed away with sterile distilled water and 
was loaded with 0.2 M nickel sulfate, then washed again with sterile distilled water and 
equilibrated with 10 mM of sodium phosphate buffer (buffer A) for loading and binding, which 
resulted in a pH of 7.3. Lysates were loaded at 0.5 ml/ min to ensure proper binding of His6-
tagged-protein. After 5 to 10 column volumes (CV) of washing (until the baseline returned to 
zero), a gradient purification procedure was performed for elution of His6-tagged-protein using 
250 mM Imidazole 10 mM of sodium phosphate buffer, pH=7.3 (buffer B). Collected fractions 




4.7 Target protein determination assay 
To ensure that the targeted protein expressed and produced properly by the host, the 
collected fraction was subjected to a protein analysis experiment. Fractions were running through 
a SDS-PAGE electrophoresis experiment. The gel then proceeded to detect His6-tag-proteins by 
two methods; western blotting and the His6-tag fluorescent kit. 
4.7.1 SDS-PAGE electrophoresis 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis is a technique used to 
separate proteins depending on their molecular mass. In short, SDS binds to denatured protein, 
and it is believed to adopt a negative charged rod-like shape. After that, an electrical field forces 
a negatively charged protein to migrate through the gel from a negative to a positive electrode. 
Proteins separate in different bands depending on their molecular mass difference. Different 
thicknesses and concentrated gels were prepared that were dependent on the experiment and 
protein separation purpose. The gel is prepared in two layers, resolving and stacking gel. 
Resolving gel is used to stock the major component that is used to prepare both gel layers 
include: 
 30 % Acrylamide  
 1 M Tris – HCl, pH 8.8 for resolving and 0.5 M Tris – HCl, pH 6.8 for stacking gel 
 10 % SDS 
 Deionized water 
 10 % APS 
 TEMED 
Denaturation of the protein is a necessary step, before loading and running of protein 




5% of 2-mercaptoethanol to reduce protein superficial and intermolecular disulfide bonds 
between protein subunits. The solution is then heated for 5 minutes at 95 °C right before added 
to the polyacrylamide gel. Electrophoresis was performed in an electrophoresis chamber filled 
with SDS-PAGE buffer by applying 180 volts for 50 minutes. After completing electrophoresis, 
the gel was rinsed by deionized water. The gel was placed in Coomassie staining buffer for 30 
minutes and left overnight to see the separated protein bands directly or subjected for further 
processing for further advancement of targeted protein validation.  
4.7.2 Detection of His6-tag using protein tag stain reagent set 
Pierce™ 6xHis Protein Tag Stain Reagent Set was purchased from ThermoFisher 
Scientific reagents. This kit is a fluorescent stain which is able to detect histidine-tagged (His-
tagged) recombinant fusion proteins in polyacrylamide gels. His-tagged recombinant proteins 
can be detected directly in the gel. The entire protocol takes 140 minutes. This method eliminates 
time-consuming membrane transfers when using a western blotting technique that is typically 
used to detect and confirm the purity of tagged proteins. After the procedure is done, his6-tag-
protein was detected using a UV lamp (300nm) or a type of detection equipment (CCD camera). 
A CCD camera is used in this study because it is more sensitive and can detect as low as 0.2 µg 
of His-tagged protein. Another advantage is that it uses the same gel for a total protein profile 
determination by staining with Coomassie protein dye. 
4.7.3 Western blot 
 After proteins are separated based on molecular weight through SDS-PAGE gel 
electrophoresis, separated proteins transfer to a membrane to detect targeted proteins with the 
specific antibody. Samples, protein markers, and a positive control run with two SDS-PAGE 




completed, the nitrocellulose membrane and the transfer gel were equilibrated in the transfer 
buffer and assembled in a blotting stack in order (as shown in assemble step in Figure 4.3).  
 
Figure 4.3 Steps of western blot gel preparation and stock diagram [78] 
The stack unit is then placed in the tank which is filled with transfer buffer (1X Towbin 
with 20% methanol). After this step, the power supply was connected and was set at 150V, 74 
mA for 2 hours. After blotting was completed, nitrocellulose membrane was a sock in 5% of 




membrane was washed with TBS-T. The membrane was kept incubated overnight in a TBS-T 
buffer containing His6-tag antibodies and 0.2% bovine serum albumin (BSA). The following 
day, the membrane was washed three times for three minutes each time with TBS-T to remove 
any excess antibodies. One milliliter of NBT/BCIP solution was added to a transfer paper. By 
using a 1 mL pipette, the same solution was poured onto the membrane until the band developed. 
To prevent the membrane from turning dark in color, the membrane was transferred into water to 

















5. Result and discussion 
5.1 Traditional shake Flask cultivation 
In this experiment, two liters of LB media supplied with 100 μg/ml ampicillin was 
inoculated with 10 ml of overnight growth. After 2 hours, arabinose was used to induce the cell 
to produce the protein of interest. Cells were harvested after 4 hours. A total of approximately 3 
grams of cell pellets were lysed and then subjected to purification by IMAC using nickel loaded 
HiTrap IMAC FF columns. IMAC chromatograms showed two peaks in 62.5 mM imidazole, as 
well as one small one eluted in 125 mM imidazole (Figure 5.1). 
 
Figure 5.1 FPLC chromatogram of cell lysate prepared by traditional shaker flask method using 




All fractions coming from these peaks were subjected to SDS-PAGE gel to check if the 
protein of interest (bFGF-CBD-CBD) had appeared. The lysate and all suspected fractions were 
covered in three gels. An equal volume from each IMAC fraction was loaded to each lane in the 
15% SDS-PAGE gel. Gel stained with Pierce™ 6xHis Protein Tag Stain Reagent and Coomassie 
Brilliant Blue staining solution showed several interesting bands in cell lysate and F# 25-29 
(Figure 5.2).  
 
Figure 5.2 SDS-PAGE gel shows IMAC fractions results of cell lysate prepared by the 
traditional shaker method. A. Gels stained with Pierce™ 6xHis Protein Tag Stain Reagent. B. 
Gels stained with Coomassie Brilliant Blue staining solution. Results for both methods included 
lane 1– molecular weight marker; 2– cell lysate after expression; 3– junk protein fraction; 4– 12, 
fraction 20-28 respectively.  
The results of 62,5 mM imidazole fraction showed a strong his6x protein signal at 





Figure 5.3 bFGF-CBD-CBD fusion protein carton shows the molecular weight of bFGF and 2 
unit of CBD. 
 This band is equivalent to an expected molecular weight of bFGF-CBD-CBD. It also 
showed a strong Hisx6 tag protein signal at approximately 28 KD. Since the designed bFGF-
CBD-CBD protein has a collagenase cleavage site between bFGF and CBD-CBD-Hisx6, it is 
interesting to note that another outcome is possible. Collagenase cleavage sites might be cleaved 
by a protease which is naturally produced in E coli-BL21. If the bFGF is released from the entire 
protein, the expected molecular weight of CBD-CBD-Hisx6 unit is 28 KD. Western blot was 
performed to specifically detect Hisx6-tag protein using Hisx6-tag antibodies. As shown by the 
western blot where the interesting fractions were run (Figure 5.4), two interesting bands; 46 KD 
and 28 KD were shown over the lysate and fraction #25 to fraction #29.  
 
Figure 5.4 Western blot of interesting IMAC fractions resulting in lysate prepared by traditional 
shaker methods.  1 – molecular weight marker; 2 – positive control (Hisx6-tag -protein; 3–cell 





 Fraction of 125 mM was also examinde using western blot. Bands were developed at 46 
KD and 28 KD in fraction #3 and #4 (figure 5.5). Result of 125 mM fraction also confirm the 
cleavage issue. This is an interesting finding that needs further investigation to validate. 
 
Figure 5.5 Coomassie Brilliant Blue staining and Western blot of the interesting heparin 
fractions of lysate prepared by traditional shaker methods. For both methods; 1 – molecular 
weight marker; 2– positive control (Hisx6-tag -protein); 3- cell lysate; 4–10 fraction 1 to 7 
respectively of 62.5 mM imidazole fraction. 
 
5.2 Fed-batch cultivation 
As mentioned previously in section 4.4.2, this method was used to produce high cell 
density. In traditional flask methods, 1-2 grams per liter was yielded as the total dry cell weight 
while 50-55 grams were produced by using fed-batch fermentation (Figure 5.6). In terms of 
biomass production, there is a varying difference between the amount produced by fed-batch 
fermentation (Figure 5.6 A) and shake flask method (Figure 5.6 B). Producing a large amount of 
biomass has an advantageous impact on manufacturing cost. The production of more cells 
subsequently results in a greater protein production yield.  
In this method, feeding profiles were used by employing an exponential feeding strategy 
as mentioned in Chapter 4. The main target of using this strategy is to produce a large number of 




fermentation. This method is used in many industrial applications to achieve production target 
with a large quantity. 
 
Figure 5.6 Biomass production of E coli BL-21 by using; A- Fed-batch fermentation method; B- 
Traditional shaker method (Image by author). 
As discussed in section 4.4.2, the entire process breaks down into two events; batch and 
fed-batch fermentation. In the batch step, L-arabinose was added to induce an expression of 
BFGF-CBD-CBD protein after approximately 2 hours from inoculation when the optical density 
(OD) reached ̴ 0.6 units (at 600 nm) to maintain the inducer availability to the new cells in the 
next event (fed-batch step). Arabinose was supplied with feed by the same percentage. Cells 




was harvested from two liters growth in 3 liters of bioreactors. Cell lysate prepared by this 
method was subjected to a purification step and followed by an expression examination. Gradient 
purification protocol (which is described in chapter 4) was performed.  
The outcome fractions of the IMAC purification technique (Figure 5.7) were examined to 
confirm the engrossing recombinant protein (bBFGF-CBD-CBD-Hisx6) expression. As shown in 
Figure 5.7, two peaks were shown in 62.5 mM imidazole fraction, and a small one is shown in 
125 mM imidazole fraction. Both fractions were subjected to a validation process to check 
targeted protein expressions using 15% SDS-PAGE gel. Similar to traditional flask culture, two 
interesting bands 46 KD, and 28 KD, were shown in the gel over the lysate and fraction #11-
fraction #14 (figure 5.8). These bands are shown using both staining methods; Pierce™ 6xHis 
Protein Tag Stain Reagent and Coomassie Brilliant Blue staining solution. As previously stated 
in section 5.1, this result confirms the same scenario of two notable bands 46 KD, and 28 KD. 
Since the 46 KD band looks small and resembles a tail buried under the other thick band (figure 
5.8), suspected fractions (fraction 9-16) were concentrated using TCA protein precipitation 
protocol. Concentrated fractions were then loaded to SDS-PAGE gel right before the protein was 
transferred to a nitrocellulose membrane to perform the western blotting technique. The western 
blotting result has confirmed the expression of Hisx6 tag-protein using specific Hisx6-tag 





Figure 5.7 FPLC purification chromatogram of cell lysate prepared by fed-batch fermentation 
using nickle-loaded HiTrap IMAC FF columns. 
 
The result shows a thick His-tag protein band at 27KD in fractions #12-16 while a thin 
band is shown at 46 KD in the same fractions. This result might confirm the bFGF cleavage 
scenario from the whole expressed protein (BFGF-CBD-CBD). This scenario might happen after 
the expression of the whole BFGF-CBD-CBD protein. Natural protease may occur by E coli and 
cleave the collagenase site that was designed between the bFGF and Josh-Hisx6 unit. This 




Figure 5.8 SDS-PAGE gel shows IMAC fractions of cell lysate prepared by the fed-batch 
method. A. Gel stained with Pierce™ 6xHis Protein Tag Stain Reagent. B. Gel stained with 
Coomassie Brilliant Blue staining solution. For both methods, lane 1 – molecular weight marker; 
2 –cell lysate after expression; 3 –11, fraction 9 -16 respectively. 
 Hisx6-tag protein bands are shown in the gel at 28 KD and 46 KD. Most of the Hisx6-tag 
protein is detected at 28 KD which also gives credit to support the cleavage scenario. His6x-tag 
protein is shown at 28 KD. All fractions including the fraction in small peak were subjected to 
the validation process to check if the whole protein (BFGF-CBD-CBD) undergoing the cleavage 
process by the host after production. 
 
Figure 5.9 Coomassie Brilliant Blue staining and Western blot of a riveting IMAC fraction of 
the lysate prepared by the fed-batch method. For both methods. 1 – molecular weight marker; 2–





5.3 Purification of BFGF-CBD-CBD protein by heparin affinity chromatography 
It has been discovered that one of the most important classes of heparin-binding protein is 
the fibroblast growth factors. Since the expressed protein in this study is fused to FGF, cell lysate 
prepared by traditional flask methods was subjected to another purification strategy using HiTrap 
Heparin HP to acquire more evidence to support the cleavage issue between bFGF and Josh-
Hisx6 unit. Cell purification was performed by FPLC. Two peaks were shown in FPLC 
chromatograms at 0.5 M NaCl fractions. Additionally, there was a small one that eluted in 1 M 
NaCl fractions (Figure 5.10). 
 
Figure 5.10 FPLC purification chromatogram of cell lysate prepared by the fed-batch method 




The results in Figure 5.11 show that the 28 KD band which represent Josh-Hisx6 has 
disappeared. This band showed Hisx6-tag protein signal in the previous experiment. This is also 
accredited to support the cleavage issue given that the FGF (which has a high binding affinity to 
heparin) is cleaved from the whole protein.  
Figure 5.11 Coomassie Brilliant Blue staining and Western blot of the interesting heparin 
fractions of lysate prepared by methods. For both methods; 1 – molecular weight marker; 2– 
positive control (Hisx6-tag -protein); 3- 9 fraction 15–21 fraction. 
 
As was produced in IMAC purification, the weak band was also shown at 46 KD in 
fraction #15, #16 and #17. This is another confirmation of what happen to the whole units of 
production. More investigations such as protein sequencing for suspected bands are necessary to 








6. Conclusions and Recommendation 
In light of the findings of the present study, bFGF-CBD-CBD is expressed by E coli BL-
21 using traditional shake flask and fed-batch cultivations. This protein can be produced in large 
amount if the major cleavage issue between CBD-CBD and bFGF can be solved. Sequencing of 
suspected protein bands is important to confirm the cleavage event. Genetic studies are also 
recommended to find the protease responsible for and knock-out its genes. Conducting further 
studies by using other E. coli hosts with genetically improved expression to produce a high yield 
of bFGF-CBD-CBD are necessary. Further biological studies are needed to evaluate the 
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8. Appendix  
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